Protocolo terapéutico del síndrome coronario crónico

  1. García Rivas, S. 1
  2. Viéitez Flórez, J.M. 1
  3. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades cardiovasculares (III)

Series: 13

Issue: 37

Pages: 2157-2160

Type: Article

DOI: 10.1016/J.MED.2021.06.024 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Chronic coronary syndrome includes the spectrum of clinical situations in which stable coronary artery disease is underlying, which could be symptomatic (stable angina). Therefore, treatment for these patients should aim to control symptoms and prevent cardiovascular events with pharmacological treatment and lifestyle changes (non-pharmacological treatment). Anti-ischaemic drugs are used for the long-term prevention of angina and the relief of acute symptoms, but most do not offer a protective benefit against cardiovascular events. Therefore, they should be used in combination with anti-thrombotic and lipid-lowering drugs, and drugs that have been demonstrated to modify cardiovascular disease.

Bibliographic References

  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck Brentano C. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesThe Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77.
  • Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP. Expert consensus document: A “diamond” approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120-32.
  • López de Sá E, Estévez Á, Onaindía J, Rubio R, López Sendón J. Papel de los nitratos en el tratamiento de la enfermedad cardiovascular. Rev Esp Cardiol. 2006;6:41A-50A.
  • Koski R, Kennedy B. Comparative review of oral P2Y12 inhibitors. P T. 2018;43(6):352-7.
  • Valgimigli M, Bueno H, Byrne R, Collet JP, Costa F, Jeppsson A. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-60.
  • Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-367.
Data source: Dialnet